PT3318259T - Composição farmacêutica estável para administração oral - Google Patents

Composição farmacêutica estável para administração oral

Info

Publication number
PT3318259T
PT3318259T PT168213247T PT16821324T PT3318259T PT 3318259 T PT3318259 T PT 3318259T PT 168213247 T PT168213247 T PT 168213247T PT 16821324 T PT16821324 T PT 16821324T PT 3318259 T PT3318259 T PT 3318259T
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
oral administration
stable pharmaceutical
stable
oral
Prior art date
Application number
PT168213247T
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57686183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3318259(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT3318259T publication Critical patent/PT3318259T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT168213247T 2015-07-03 2016-07-01 Composição farmacêutica estável para administração oral PT3318259T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015134817 2015-07-03

Publications (1)

Publication Number Publication Date
PT3318259T true PT3318259T (pt) 2023-03-20

Family

ID=57686183

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168213247T PT3318259T (pt) 2015-07-03 2016-07-01 Composição farmacêutica estável para administração oral

Country Status (21)

Country Link
US (9) US10786500B2 (pt)
EP (2) EP3318259B1 (pt)
JP (2) JP6132294B1 (pt)
KR (1) KR20180023914A (pt)
CN (1) CN107847500B (pt)
CA (1) CA2989534C (pt)
DK (1) DK3318259T3 (pt)
ES (1) ES2940306T3 (pt)
FI (1) FI3318259T3 (pt)
HK (1) HK1248544A1 (pt)
HR (1) HRP20230253T1 (pt)
HU (1) HUE061697T2 (pt)
LT (1) LT3318259T (pt)
MX (1) MX2017016862A (pt)
PH (1) PH12017502252B1 (pt)
PL (1) PL3318259T3 (pt)
PT (1) PT3318259T (pt)
RS (1) RS64070B1 (pt)
SI (1) SI3318259T1 (pt)
TW (1) TWI756177B (pt)
WO (1) WO2017006855A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606413RA (en) * 2014-02-04 2016-09-29 Astellas Pharma Inc Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
HUE061697T2 (hu) * 2015-07-03 2023-08-28 Astellas Pharma Inc Stabil gyógyszerkészítmény orális adagolásra
MX2021012033A (es) * 2019-04-03 2021-11-03 Astellas Pharma Inc Composicion farmaceutica.
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5352474B2 (ja) * 2007-12-28 2013-11-27 沢井製薬株式会社 口腔内崩壊錠およびその製造方法
RS57045B1 (sr) * 2009-05-08 2018-05-31 Astellas Pharma Inc Jedinjenje diamino heterocikličnog karboksamida
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
SG11201606413RA (en) 2014-02-04 2016-09-29 Astellas Pharma Inc Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
HUE061697T2 (hu) * 2015-07-03 2023-08-28 Astellas Pharma Inc Stabil gyógyszerkészítmény orális adagolásra
US9755832B2 (en) 2015-12-29 2017-09-05 International Business Machines Corporation Password-authenticated public key encryption and decryption

Also Published As

Publication number Publication date
CA2989534C (en) 2023-08-01
US20200383977A1 (en) 2020-12-10
TWI756177B (zh) 2022-03-01
SI3318259T1 (sl) 2023-06-30
TW201716069A (zh) 2017-05-16
US20230129146A1 (en) 2023-04-27
US10786500B2 (en) 2020-09-29
US11938131B2 (en) 2024-03-26
US20230277529A1 (en) 2023-09-07
US11944620B2 (en) 2024-04-02
CA2989534A1 (en) 2017-01-12
CN107847500B (zh) 2021-08-10
EP3318259B1 (en) 2023-01-11
JP6132294B1 (ja) 2017-05-24
US20180185359A1 (en) 2018-07-05
RU2764750C2 (ru) 2022-01-20
PL3318259T3 (pl) 2023-05-02
DK3318259T3 (en) 2023-03-06
US20230277530A1 (en) 2023-09-07
EP4230208A1 (en) 2023-08-23
EP3318259A1 (en) 2018-05-09
PH12017502252A1 (en) 2018-05-28
JP6798400B2 (ja) 2020-12-09
EP3318259A4 (en) 2019-02-27
ES2940306T3 (es) 2023-05-05
FI3318259T3 (fi) 2023-03-20
US11938132B2 (en) 2024-03-26
HUE061697T2 (hu) 2023-08-28
PH12017502252B1 (en) 2018-05-28
US20230310422A1 (en) 2023-10-05
WO2017006855A1 (ja) 2017-01-12
HK1248544A1 (zh) 2018-10-19
JP2017119728A (ja) 2017-07-06
US20230277532A1 (en) 2023-09-07
LT3318259T (lt) 2023-05-10
RU2018103354A3 (pt) 2019-11-28
RU2018103354A (ru) 2019-08-05
US11938130B2 (en) 2024-03-26
US20230277531A1 (en) 2023-09-07
KR20180023914A (ko) 2018-03-07
US20230301992A1 (en) 2023-09-28
HRP20230253T1 (hr) 2023-04-28
RS64070B1 (sr) 2023-04-28
JPWO2017006855A1 (ja) 2017-07-13
MX2017016862A (es) 2018-04-24
US11938133B2 (en) 2024-03-26
CN107847500A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
IL270812A (en) Solid compositions for oral drug administration
HK1254343A1 (zh) 藥物製劑
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
ZA201601656B (en) Inhalable pharmaceutical composition
HK1231390A1 (zh) 用於局部給藥的藥用組合物
IL262204A (en) Granular formulation for oral administration
HUE051900T2 (hu) Íz-leplezett orális gyógyászati készítmény
IL254794A0 (en) Pharmaceutical formulations
HK1245646A1 (zh) 口服給藥用醫藥組合物
HK1255345A1 (zh) 含有高濃度紫杉烷的用於口服給藥的藥物組合物
HK1232144A1 (zh) 經口給藥用醫藥組合物
PT3650024T (pt) Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência
SI3377044T1 (sl) Ibuprofenski sestavki za neposredno oralno dajanje
EP3326652A4 (en) Pharmaceutical composition for oral administration comprising high concentration taxane
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION